Loading
H3C2 (Histone H3.1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Bladder & urothelial cancer, Oesophageal cancer and 5 more.
Core component of nucleosome. Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template. Histones thereby play a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability.
CIViC holds 7 clinical evidence items and 1 assertion across 1 variant. Open Targets scores its association with cancer at 0.73 (direct and indirect evidence; datatypes literature 0.04, affected pathway 0.76, somatic mutation 0.78). IntOGen calls it a driver in 5 cohorts (4 activating, 1 loss-of-function), covering Bladder Urothelial Carcinoma, Invasive Breast Carcinoma, Diffuse Large B-Cell Lymphoma, NOS, Oesophageal Adenocarcinoma.
In plain words · H3C2 (Histone H3.1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Bladder & urothelial cancer, Oesophageal cancer and 5 more.
H3C2 (Histone H3.1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Bladder & urothelial cancer, Oesophageal cancer and 5 more.
Core component of nucleosome. Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template.
No product in this corpus aims at H3C2 yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA H3C2: RNA group enriched (bone marrow 6 nTPM, lymphoid tissue 2 nTPM); high antibody staining in 44 normal tissues; highest cancer staining glioma (12 of 12 high). Distribution: 5 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Breast cancer (all types), Bladder & urothelial cancer, Oesophageal cancer, Lymphoma, Brain and spinal cord tumours (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P68431; CIViC gene H3C2; IntOGen H3C2; Human Protein Atlas H3C2 tissue; Open Targets ENSG00000286522 associations
First described 1981. Earliest sequence paper UniProt cites for the protein: Ohe et al, J. Biochem, 1981, "Human spleen histone H3. Isolation and amino acid sequence". Source.
Sources: HGNC HGNC:4776 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P68431 (protein name, function text, keywords and locations (REST API)); CIViC gene H3C2 (7 evidence items, 1 assertions, 1 variants; diseases: Diffuse Midline Glioma, H3 K27-altered, Glioblastoma, Anaplastic Astrocytoma, Brain Glioblastoma Multiforme, Diffuse Astrocytoma (GraphQL API, CC0)); Open Targets ENSG00000286522 (association with cancer (MONDO_0004992) 0.73; per-cancer scores at or above 0.5: non-Hodgkin lymphoma 0.51, breast cancer 0.64 (GraphQL API, CC0)); IntOGen H3C2 (driver in 5 cohorts (Act 4, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Core component of nucleosome. Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template. Histones thereby play a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability. DNA accessibility is regulated via a complex set of post-translational modifications of histones, also called histone code, and nucleosome remodeling. Location: Nucleus; Chromosome (UniProt). Locus 6p22.2 (HGNC).
RNA: group enriched (bone marrow 6 nTPM, lymphoid tissue 2 nTPM), detected in some normal tissues.
Medium: Oral mucosa.
RNA cancer enhanced: Bladder Urothelial Carcinoma 15 pTPM, Colon Adenocarcinoma 21 pTPM.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"H3C2" OR ABSTRACT:"H3C2" OR TITLE:"H3 clustered histone 2" OR ABSTRACT:"H3 clustered histone 2" OR TITLE:"Histone H3.1" OR ABSTRACT:"Histone H3.1" OR TITLE:"H3/l" OR ABSTRACT:"H3/l" OR TITLE:"H3FL" OR ABSTRACT:"H3FL" OR TITLE:"HIST1H3B" OR ABSTRACT:"HIST1H3B") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about H3C2, not a curated reading list.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, CIViC, IntOGen.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen, Breast cancer (all types).
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen, Open Targets Platform.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, CIViC, IntOGen.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen, Open Targets Platform.
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen, Breast cancer (all types).
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen, Breast cancer (all types).
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen, Breast cancer (all types).